Chromocell Therapeutics (CHRO) Stock Chart & Stock Price History $0.64 -0.01 (-1.45%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Chromocell Therapeutics Stock Price Performance 5 Day Performance+8.15%1 Month Performance-2.50%3 Month Performance-24.29%6 Month Performance-53.03% Receive CHRO Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. CHRO Stock Chart for Sunday, December, 22, 2024 CHRO Chart by TradingView Chromocell Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/20/2024$0.65$0.64-1.45%$0.65$0.56166,766 shs$3.88 million12/19/2024$0.59$0.65+10.68%$0.65$0.59159,160 shs$3.94 million12/18/2024$0.60$0.59-0.84%$0.69$0.56662,177 shs$3.56 million12/17/2024$0.59$0.60+0.66%$0.62$0.5824,550 shs$3.59 million12/16/2024$0.59$0.59+1.03%$0.60$0.5828,975 shs$3.56 million12/13/2024$0.69$0.59-15.08%$0.68$0.58153,515 shs$3.53 million Get the Latest News and Ratings for CHRO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/12/2024$0.58$0.69+18.79%$0.71$0.6360,907 shs$4.15 million12/11/2024$0.61$0.58-4.34%$0.66$0.58153,176 shs$3.50 million12/10/2024$0.71$0.61-14.18%$0.68$0.58156,116 shs$3.66 million12/09/2024$0.83$0.71-15.38%$0.79$0.65137,228 shs$4.26 million12/06/2024$0.66$0.83+26.31%$0.88$0.62991,567 shs$5.03 million12/05/2024$0.64$0.66+4.01%$0.68$0.6228,579 shs$3.99 million12/04/2024$0.59$0.64+7.71%$0.68$0.6311,314 shs$3.83 million12/03/2024$0.66$0.59-11.14%$0.69$0.55128,192 shs$4 million12/02/2024$0.61$0.66+8.67%$0.78$0.59110,346 shs$4.00 million11/29/2024$0.63$0.63-0.05%$0.63$0.5924,435 shs$3.77 million11/28/2024$0.63$0.63$0.65$0.6039,860 shs$3.77 million11/27/2024$0.60$0.63+4.53%$0.65$0.6039,860 shs$3.77 million11/26/2024$0.64$0.60-6.53%$0.66$0.609,898 shs$3.61 million11/25/2024$0.66$0.64-3.03%$0.65$0.5920,774 shs$3.86 million11/22/2024$0.63$0.66+4.56%$0.66$0.6084,035 shs$3.98 million11/21/2024$0.62$0.63+1.94%$0.67$0.5152,687 shs$3.81 million Related Companies NRx Pharmaceuticals Stock Chart Cara Therapeutics Stock Chart Acurx Pharmaceuticals Stock Chart AIM ImmunoTech Stock Chart TherapeuticsMD Stock Chart HCW Biologics Stock Chart Marinus Pharmaceuticals Stock Chart PharmaCyte Biotech Stock Chart Aspira Women's Health Stock Chart Sol-Gel Technologies Stock Chart Receive CHRO Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:CHRO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
